Triple therapy AMD trial to continue
The Phase II RADICAL study (Reduced Fluence Visudyne Anti-VEGF-Dexamethasone In Combination for AMD Lesions) is to continue as planned, following promising interim results and the positive recommendations of the independent Data and Safety Monitoring Committee.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Recent Videos
Related Content
